An Overview of Thrombin Inhibitors in the Perspective of Structure-activity Relationships

被引：3

作者：

Wang, Jiangming ^{[1
]}

Sun, Xiaojing ^{[1
]}

Li, Na ^{[1
]}

Sheng, Ruilong ^{[2
]}

Guo, Ruihua ^{[1
,3
,4
]}

机构：

[1] Shanghai Ocean Univ, Coll Food Sci & Technol, Shanghai 201306, Peoples R China

[2] Univ Madeira, CQM Cent Quim Madeira, Campus Penteada, P-9000390 Funchal, Portugal

[3] Shanghai Engn Res Ctr Aquat Prod Proc & Preservat, Shanghai 201306, Peoples R China

[4] Minist Agr, Lab Qual & Safety Risk Assessment Aquat Prod Stora, Shanghai 201306, Peoples R China

来源：

CURRENT MEDICINAL CHEMISTRY | 2023年 / 30卷 / 25期

基金：

中国国家自然科学基金;

关键词：

Antithrombotic; thrombin inhibitor; structure-activity relationship; pharmacokinetics; PROTEASE-ACTIVATED RECEPTORS; DESIGNING ALLOSTERIC REGULATORS; OPTIMIZING PLATELET INHIBITION; ORALLY BIOAVAILABLE SERIES; FACTOR XA INHIBITORS; BIOLOGICAL EVALUATION; ANTITHROMBOTIC COMPOUNDS; IN-VITRO; PART; SCUTELLAREIN DERIVATIVES;

D O I：

10.2174/0929867329666220906105200

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Thrombosis is one of the most important pathogenic factors related to cardiovascular diseases. Presently, thrombin inhibitors have gradually gained prominence in clinical practice due to their unique potential, such as dabigatran. Nevertheless, the risk of bleeding is not completely eliminated, and the threats of gastrointestinal bleeding are even increased in some cases. Therefore, developing new oral thrombin inhibitors with low side effects is urgent. In this paper, we summarized recent advances in the newly synthesized and isolated thrombin inhibitors from 2000 to 2019 and their structure-activity relationships (SARs) along with structure-dependent pharmacokinetic parameters, guiding the next generation of oral thrombin inhibitors.

引用

页码：2864 / 2930

页数：67

共 50 条

[1] Structure-activity relationships for synthetic peptide inhibitors of thrombin
Clement, CC
Gingold, J
Philipp, M
FASEB JOURNAL, 2003, 17 (05): : A1006 - A1006
[2] Structure-activity relationships for synthetic peptide inhibitors of thrombin.
Clement, CC
Philipp, M
Gingold, J
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U214 - U214
[3] A Series of Natural Flavonoids as Thrombin Inhibitors: Structure-activity relationships
Liu, Li
Ma, Hongyue
Yang, Nianyun
Tang, Yuping
Guo, Jianming
Tao, Weiwei
Duan, Jin'ao
THROMBOSIS RESEARCH, 2010, 126 (05) : E365 - E378
[4] A perspective on quantitative structure-activity relationships and carbonic anhydrase inhibitors
Clare, Brian W.
Supuran, Claudiu. T.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (01) : 113 - 137
[5] Synthesis and structure-activity relationships of potent thrombin inhibitors: Piperazides of 3-amidinophenylalanine
Sturzebecher, J
Prasa, D
Hauptmann, J
Vieweg, H
Wilkstrom, P
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (19) : 3091 - 3099
[6] Structure-activity relationships for synthetic peptides and peptidomimetics of thrombin
Clement, CC
Philipp, M
BIOCHEMISTRY, 2003, 42 (28) : 8631 - 8631
[7] Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists
Ahn, HS
Arik, L
Boykow, G
Burnett, DA
Caplen, MA
Czarniecki, M
Domalski, MS
Foster, C
Manna, M
Stamford, AW
Wu, YS
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (14) : 2073 - 2078
[8] Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships
Poli, Giulio
Di Fabio, Romano
Ferrante, Luca
Summa, Vincenzo
Botta, Maurizio
CHEMMEDCHEM, 2017, 12 (23) : 1917 - 1926
[9] STRUCTURE-ACTIVITY RELATIONSHIPS IN ADENOSINE DEAMINASE INHIBITORS
SCHAEFFE.HJ
JOHNSON, RN
ODIN, E
HANSCH, C
JOURNAL OF MEDICINAL CHEMISTRY, 1970, 13 (03) : 452 - &
[10] Structure-activity relationships of adenosine deaminase inhibitors
Vittori, S
Camaioni, E
Costanzi, S
Volpini, R
Lupidi, G
Cristalli, G
NUCLEOSIDES & NUCLEOTIDES, 1999, 18 (4-5): : 741 - 742

← 1 2 3 4 5 →